Research ExplorerPublicationsTherapeutic approaches for refractory germ cell cancer

Therapeutic approaches for refractory germ cell cancer

Standard

Therapeutic approaches for refractory germ cell cancer. / Oing, Christoph; Seidel, Christoph; Bokemeyer, Carsten.

In: EXPERT REV ANTICANC, Vol. 18, No. 4, 04.2018, p. 389-397.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Oing, C, Seidel, C & Bokemeyer, C 2018, 'Therapeutic approaches for refractory germ cell cancer', EXPERT REV ANTICANC, vol. 18, no. 4, pp. 389-397. https://doi.org/10.1080/14737140.2018.1450630

APA

Oing, C., Seidel, C., & Bokemeyer, C. (2018). Therapeutic approaches for refractory germ cell cancer. EXPERT REV ANTICANC, 18(4), 389-397. https://doi.org/10.1080/14737140.2018.1450630

Vancouver

Oing C, Seidel C, Bokemeyer C. Therapeutic approaches for refractory germ cell cancer. EXPERT REV ANTICANC. 2018 Apr;18(4):389-397. https://doi.org/10.1080/14737140.2018.1450630

Bibtex

@article{da028fda00964776b5a51b210c47f9c2,
title = "Therapeutic approaches for refractory germ cell cancer",
abstract = "INTRODUCTION: Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metastasized patients ultimately developing platinum-resistant and fatal disease. Areas covered: Based on a comprehensive literature search of MEDLINE, EMBASE and conference proceedings of ESMO, ASCO and EAU meetings, this review provides an overview on current and potential future treatment options for platinum-refractory germ cell cancer patients including cytostatics and molecularly targeted therapies. Expert commentary: Treatment of platinum-refractory disease remains challenging and long-term survival is rarely achieved despite multimodal treatment approaches. Targeted treatment approaches do not yet play a role in the treatment of platinum-refractory disease due to lacking efficacy in small, unselected clinical trials. Inclusion of patients into clinical trials is strongly recommended.",
keywords = "Journal Article",
author = "Christoph Oing and Christoph Seidel and Carsten Bokemeyer",
year = "2018",
month = apr,
doi = "10.1080/14737140.2018.1450630",
language = "English",
volume = "18",
pages = "389--397",
journal = "EXPERT REV ANTICANC",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "4",

}

RIS

TY - JOUR

T1 - Therapeutic approaches for refractory germ cell cancer

AU - Oing, Christoph

AU - Seidel, Christoph

AU - Bokemeyer, Carsten

PY - 2018/4

Y1 - 2018/4

N2 - INTRODUCTION: Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metastasized patients ultimately developing platinum-resistant and fatal disease. Areas covered: Based on a comprehensive literature search of MEDLINE, EMBASE and conference proceedings of ESMO, ASCO and EAU meetings, this review provides an overview on current and potential future treatment options for platinum-refractory germ cell cancer patients including cytostatics and molecularly targeted therapies. Expert commentary: Treatment of platinum-refractory disease remains challenging and long-term survival is rarely achieved despite multimodal treatment approaches. Targeted treatment approaches do not yet play a role in the treatment of platinum-refractory disease due to lacking efficacy in small, unselected clinical trials. Inclusion of patients into clinical trials is strongly recommended.

AB - INTRODUCTION: Most germ cell cancer patients with metastatic disease are cured by cisplatin-based combination chemotherapy. 30% of metastatic patients will develop relapse or progress despite adequate first-line treatment and will require salvage therapy, with about 10% of metastasized patients ultimately developing platinum-resistant and fatal disease. Areas covered: Based on a comprehensive literature search of MEDLINE, EMBASE and conference proceedings of ESMO, ASCO and EAU meetings, this review provides an overview on current and potential future treatment options for platinum-refractory germ cell cancer patients including cytostatics and molecularly targeted therapies. Expert commentary: Treatment of platinum-refractory disease remains challenging and long-term survival is rarely achieved despite multimodal treatment approaches. Targeted treatment approaches do not yet play a role in the treatment of platinum-refractory disease due to lacking efficacy in small, unselected clinical trials. Inclusion of patients into clinical trials is strongly recommended.

KW - Journal Article

U2 - 10.1080/14737140.2018.1450630

DO - 10.1080/14737140.2018.1450630

M3 - SCORING: Review article

C2 - 29516750

VL - 18

SP - 389

EP - 397

JO - EXPERT REV ANTICANC

JF - EXPERT REV ANTICANC

SN - 1473-7140

IS - 4

ER -